Alcon, the global leader in eye care, has announced the launch of wavelight plus, India’s first fully personalised Laser-Assisted In Situ Keratomileusis (LASIK) treatment.
Alcon is a leader in refractive vision correction and its next-generation wavelight plus technology introduces a new era of precision in refractive surgery, with unprecedented levels of personalisation offering patients outstanding visual outcomes with minimal risk and excellent predictability. Wavelight plus has received Central Drugs Standard Control Organisation (CDSCO) India approval, CE Mark and recently received US Food and Drug Administration (FDA) approval.
Myopia is the most common refractive error, and globally, more than 30% of the population currently suffers from myopia. This number is expected to grow to nearly 50% by 2050. In India, cases of refractive errors are steadily increasing because of factors like increased screen time, reduced outdoor activities and lifestyle changes.
Unlike conventional Lasik treatment, wavelight plus uses Ray Tracing Technology to create a Digital Eye Twin, a highly detailed 3D model of each patient’s eye. This allows surgeons to simulate, test and optimise a fully customised treatment plan before surgery, ensuring a high level of accuracy and personalised vision correction. By considering the complete optical system rather than just the cornea, this innovation enhances surgical precision, safety and visual outcomes, often enabling patients to achieve vision beyond 20/20.
Wavelight plus was first launched in China. It is available in several markets in Europe, Asia, and has recently received approval in the US.
